Trovagene (TROV) Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in AML



  • Summary:

     

    Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

    Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicineâ„¢ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including leukemia, prostate and colorectal, today announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.

    The data show that onvansertib, as a single agent, inhibits tumor growth in venetoclax (Venclexta® - Abbvie) resistant in-vitro and in-vivo models. Additionally, the data also demonstrate synergy with the combination of onvansertib and venetoclax, providing further support for t ...

     

     

    Read Full News: https://www.streetinsider.com/Corporate+News/Trovagene+(TROV)+Announces+Data+Showing+Ability+of+Onvansertib+to+Rescue+Venetoclax-Resistance+in+AML/16208088.html


Log in to reply